Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;23(S1):S27-S34.
doi: 10.1089/dia.2021.0007.

Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring

Melanie A Jackson  1 , Andrew Ahmann  2 , Viral N Shah  3
Affiliations
Review

Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring

Melanie A Jackson et al. Diabetes Technol Ther. 2021 Mar.

Abstract

The role of continuous glucose monitoring (CGM) in type 1 diabetes (T1D) is well established in improving glycemic control and reducing hypoglycemia. Type 2 diabetes (T2D) is more prevalent than T1D and management of T2D is more heterogeneous, requiring treatment ranging from lifestyle modification to oral medications to intensive insulin therapy. Recent randomized controlled trials in intensively insulin-treated T2D demonstrated the efficacy and safety of real-time CGM (rtCGM) in reducing glycated hemoglobin without increasing hypoglycemia. Although evidence is limited, early studies have indicated a role for rtCGM in selected patients with non-insulin requiring T2D to improve glycemic control and/or reduce hypoglycemia. Based on literature review, we summarized current data on the use of rtCGM in T2D management and provided future research direction to generate more evidence on the utility of CGM in this population.

Keywords: Continuous glucose monitor; Glucose monitoring; Glycemic control; HbA1c; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

M.A.J. reports no conflict of interests. A.A. receives research support from Dexcom and is on the advisory board for Medtronic. V.N.S. reports receiving research grants through University of Colorado from Sanofi, Eli-Lilly, NovoNordisk, vTv Therapeutics, Mylan GmbH, Dexcom, and Insulet. V.N.S. had served on advisory board for Sanofi and Medscape LLC.

References

    1. Polonsky WH, Fisher L, Hessler D, Edelman SV: A survey of blood glucose monitoring in patients with type 2 diabetes: are recommendations from health care professionals being followed? Curr Med Res Opin 2011;27 Suppl 3:31–37 - PubMed
    1. Rossi MC, Lucisano G, Ceriello A, et al. : Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement. Acta Diabetol 2018;55:1059–1066 - PubMed
    1. American Diabetes Association: Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S73–S84 - PubMed
    1. Battelino T, Danne T, Bergenstal RM, et al. : Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42:1593–1603 - PMC - PubMed
    1. U.K. Prospective Diabetes Study Group: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–1258 - PubMed

MeSH terms